Shandong Lukang PharmaceuticalLtd Past Earnings Performance
Past criteria checks 4/6
Shandong Lukang PharmaceuticalLtd has been growing earnings at an average annual rate of 17.7%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 11.9% per year. Shandong Lukang PharmaceuticalLtd's return on equity is 10.3%, and it has net margins of 6.6%.
Key information
17.7%
Earnings growth rate
17.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 11.9% |
| Return on equity | 10.3% |
| Net Margin | 6.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shandong Lukang PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 6,082 | 401 | 807 | 339 |
| 30 Jun 24 | 6,240 | 415 | 849 | 358 |
| 31 Mar 24 | 6,276 | 268 | 835 | 354 |
| 31 Dec 23 | 6,147 | 246 | 811 | 346 |
| 30 Sep 23 | 6,300 | 239 | 750 | 299 |
| 30 Jun 23 | 6,122 | 201 | 747 | 280 |
| 31 Mar 23 | 5,960 | 139 | 754 | 276 |
| 31 Dec 22 | 5,621 | 138 | 696 | 264 |
| 30 Sep 22 | 5,402 | 92 | 727 | 280 |
| 30 Jun 22 | 5,207 | 87 | 695 | 288 |
| 31 Mar 22 | 4,954 | 86 | 675 | 271 |
| 31 Dec 21 | 4,924 | 89 | 699 | 266 |
| 30 Sep 21 | 4,714 | 86 | 713 | 242 |
| 30 Jun 21 | 4,608 | 70 | 682 | 219 |
| 31 Mar 21 | 4,546 | 270 | 692 | 212 |
| 31 Dec 20 | 4,205 | 228 | 627 | 193 |
| 30 Sep 20 | 4,067 | 250 | 617 | 171 |
| 30 Jun 20 | 3,879 | 268 | 646 | 157 |
| 31 Mar 20 | 3,756 | 79 | 682 | 144 |
| 31 Dec 19 | 3,733 | 121 | 702 | 141 |
| 30 Sep 19 | 3,687 | 119 | 758 | 135 |
| 30 Jun 19 | 3,606 | 120 | 746 | 129 |
| 31 Mar 19 | 3,389 | 119 | 689 | 132 |
| 31 Dec 18 | 3,330 | 161 | 674 | 126 |
| 30 Sep 18 | 3,089 | 215 | 584 | 120 |
| 30 Jun 18 | 2,901 | 205 | 456 | 159 |
| 31 Mar 18 | 2,843 | 192 | 458 | 124 |
| 31 Dec 17 | 2,599 | 114 | 434 | 97 |
| 30 Sep 17 | 2,576 | 51 | 432 | 69 |
| 30 Jun 17 | 2,542 | 48 | 520 | 0 |
| 31 Mar 17 | 2,492 | 38 | 509 | 0 |
| 31 Dec 16 | 2,506 | 29 | 497 | 0 |
| 30 Sep 16 | 2,485 | 29 | 466 | 0 |
| 30 Jun 16 | 2,500 | 20 | 441 | 0 |
| 31 Mar 16 | 2,433 | 9 | 404 | 0 |
| 31 Dec 15 | 2,410 | 8 | 388 | 0 |
| 30 Sep 15 | 2,296 | -46 | 376 | 0 |
| 30 Jun 15 | 2,303 | -75 | 381 | 0 |
| 31 Mar 15 | 2,352 | -104 | 407 | 0 |
| 31 Dec 14 | 2,312 | -125 | 409 | 0 |
| 30 Sep 14 | 2,298 | -17 | 450 | 0 |
| 30 Jun 14 | 2,195 | -15 | 439 | 0 |
| 31 Mar 14 | 2,169 | -10 | 414 | 0 |
| 31 Dec 13 | 2,211 | 11 | 405 | 0 |
Quality Earnings: 600789 has a large one-off gain of CN¥247.9M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 600789's current net profit margins (6.6%) are higher than last year (3.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600789's earnings have grown by 17.7% per year over the past 5 years.
Accelerating Growth: 600789's earnings growth over the past year (67.7%) exceeds its 5-year average (17.7% per year).
Earnings vs Industry: 600789 earnings growth over the past year (67.7%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 600789's Return on Equity (10.3%) is considered low.